miR‑197‑3p‑induced downregulation of lysine 63 deubiquitinase promotes cell proliferation and inhibits cell apoptosis in lung adenocarcinoma cell lines

Chen,Yang; Yang,Chunlu

doi:10.3892/mmr.2017.8333

miR‑197‑3p‑induced downregulation of lysine 63 deubiquitinase promotes cell proliferation and inhibits cell apoptosis in lung adenocarcinoma cell lines

Authors:
- Yang Chen
- Chunlu Yang
View Affiliations

Affiliations: Department of Thoracic Surgery, Chest Hospital of Shenyang, Shenyang, Liaoning 110044, P.R. China, Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: December 20, 2017 https://doi.org/10.3892/mmr.2017.8333
Pages: 3921-3927
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is a common cause of cancer-associated mortality. The dysregulation of microRNA (miR) expression has been reported to induce lung carcinogenesis. In the present study, miR‑197‑3p upregulation was detected within LUAD tissues compared with in adjacent noncancerous tissues. The suppression of miR‑197‑3p expression was confirmed to inhibit proliferative ability and induce apoptosis of LUAD cell lines; miR‑197‑3p overexpression within the HBE cell line exhibited opposing effects. Via in silico modeling, western blot analyses and dual‑luciferase assays, it was confirmed that miR‑197‑3p directly targets the lysine 63 deubiquitinase (CYLD) gene. In the present study, the expression of miR‑197‑3p was negatively associated with CYLD mRNA expression within LUAD cell lines. In conclusion, the findings of the present study have provided novel insight into the association of miR‑197‑3p with LUAD proliferation and apoptotic regulation; the miR‑197‑3p/CYLD axis may serve as a novel potential therapeutic target for the treatment of LUAD.

View Figures

View References

1	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
2	Diaz-Garcia CV, Agudo-López A, Perez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J, Cortijo A, Martínez-Villanueva M, Iglesias L, García-Carbonero R, et al: DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: Implications for outcomes and histologic classification. Carcinogenesis. 34:1031–1038. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lau NC, Lim LP, Weinstein EG and Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 294:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
4	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
5	Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M and De Maria R: Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 21:774–782. 2014. View Article : Google Scholar : PubMed/NCBI
6	Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, et al: Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 25:160–165. 2000. View Article : Google Scholar : PubMed/NCBI
7	Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G: The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 424:801–805. 2003. View Article : Google Scholar : PubMed/NCBI
8	Lin X, Chen Q, Huang C and Xu X: CYLD promotes TNF-α-Induced cell necrosis mediated by RIP-1 in human lung cancer cells. Mediators Inflamm. 2016:15427862016. View Article : Google Scholar : PubMed/NCBI
9	Wang YY, Wu ZY, Wang GC, Liu K, Niu XB, Gu S and Meng JS: LINC00312 inhibits the migration and invasion of bladder cancer cells by targeting miR-197-3p. Tumour Biol. 37:14553–14563. 2016. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Travis WD: Pathology of lung cancer. Clin Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
12	Wang YY, Wu ZY, Wang GC, Liu K, Niu XB, Gu S and Meng JS: LINC00312 inhibits the migration and invasion of bladder cancer cells by targeting miR-197-3p. Tumour Biol. 37:14553–14563. 2016. View Article : Google Scholar : PubMed/NCBI
13	Chen X, Xu Y, Cao X, Chen Y, Jiang J and Wang K: Associations of Il-1 Family-Related polymorphisms with gastric cancer risk and the role of Mir-197 In Il-1f5 Expression. Medicine (Baltimore). 94:e19822015. View Article : Google Scholar : PubMed/NCBI
14	Lim JH, Jono H, Komatsu K, Woo CH, Lee J, Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, et al: CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun. 3:7712012. View Article : Google Scholar : PubMed/NCBI
15	Tauriello DV, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H and Maurice MM: Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell. 37:607–619. 2010. View Article : Google Scholar : PubMed/NCBI
16	Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C and Massoumi R: CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 35:461–468. 2014. View Article : Google Scholar : PubMed/NCBI
17	Wang WY, Lim JH and Li JD: Synergistic and feedback signaling mechanisms in the regulation of inflammation in respiratory infections. Cell Mol Immunol. 9:131–135. 2012. View Article : Google Scholar : PubMed/NCBI
18	Gautheron J and Luedde T: A novel player in inflammation and cancer: The deubiquitinase CYLD controls HCC development. J Hepatol. 57:937–939. 2012. View Article : Google Scholar : PubMed/NCBI
19	Font-Burgada J, Seki E and Karin M: CYLD and HCC: When being too sensitive to your dirty neighbors results in self-destruction. Cancer Cell. 21:711–712. 2012. View Article : Google Scholar : PubMed/NCBI
20	Urbanik T, Köhler BC, Boger RJ, Wörns MA, Heeger S, Otto G, Hövelmeyer N, Galle PR, Schuchmann M, Waisman A and Schulze-Bergkamen H: Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 38:121–131. 2011.PubMed/NCBI
21	Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, et al: Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat. 143:447–457. 2014. View Article : Google Scholar : PubMed/NCBI